NASDAQ: CURXCuranex Pharmaceuticals Inc Stock
$0.47+0.00 (+0%)
Updated Nov 26, 2025
CURX Price
$0.47
Fair Value Price
N/A
Market Cap
$13.43M
52 Week Low
$0.38
52 Week High
$9.18
P/E
-6.77x
P/B
0.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.01
Operating Cash Flow
-$10M
Beta
2.55
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CURX Overview
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CURX's potential to beat the market
- CURX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CURX
RankedUnranked of 485
RankedUnranked of 485
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.88 | A | |
| $340.64 | A | |
| $16.37 | A |
Be the first to know about important CURX news, forecast changes, insider trades & much more!
CURX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CURX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CURX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CURX is good value based on its book value relative to its share price (0.94x), compared to the US Biotechnology industry average (5.32x)
P/B vs Industry Valuation
CURX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CURX due diligence checks available for Premium users.
Valuation
CURX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.77x
Industry
206.11x
Market
44.79x
CURX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.94x
Industry
5.32x
CURX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CURX's financial health
Profit margin
Revenue
$0.0
Net Income
-$954.1k
Profit Margin
0%
CURX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.5M
Liabilities
$186.0k
Debt to equity
0.01
CURX's short-term assets ($14.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CURX's short-term assets ($14.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CURX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.2M
Investing
$0.0
Financing
$14.9M
CURX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CURX vs Biotech Stocks
Curanex Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.